Pelcitoclax Clinical Trials

1 actively recruiting trial across 1 location

Also known as: APG 1252, APG-1252, APG1252, Bcl-2/Bcl-XL Inhibitor APG-1252

Filter by location:

Atlanta, Georgia1 trial

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

Emory University Hospital/Winship Cancer Institute

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.